Asset
Barzolvolimab
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04146129 | phase1 | completed | 2019-10-29 | 2020-04-06 | Celldex Therapeutics | A Phase 1 Study of CDX-0159 |
| NCT05031624 | phase1 | completed | 2021-08-30 | 2022-01-14 | Celldex Therapeutics | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects |
| NCT04548869 | phase1 | completed | 2020-11-24 | 2022-12-16 | Celldex Therapeutics | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria |
| NCT04538794 | phase1 | completed | 2020-09-24 | 2023-01-17 | Celldex Therapeutics | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria |
| NCT04944862 | phase1 | completed | 2021-11-08 | 2023-07-31 | Celldex Therapeutics | A Study of CDX-0159 in Patients With Prurigo Nodularis |
FDA applications (0)
This company has no applications containing this asset.